Search bioRxiv⌕ Search

bioRxiv · 10.1101/2024.11.02.621654

A Quantitative Approach for Assessing Multidrug Resistance in Cancer

Abstract

Multidrug resistance (MDR) is a primary barrier to successful cancer treatment with small molecule drugs. One mechanism of resistance is through transporters which pump drug out of cancer cells before they exert any therapeutic effect. The most studied transporter is P-glycoprotein (Pgp), a member of the ATP Binding Cassette (ABC) superfamily of drug pumps. Prior research has focused on determining whether drugs are substrates of Pgp. Pgp specificity for FDA approved drugs is currently unclear due to technical variability in assays that quantify enzyme kinetics using non-cellular experimental models. Unfortunately, there is extreme variability in enzyme parameters for drugs that are characterized and gaps in literature for drugs that have not been characterized. Thus, our overall goal is to develop live cell methods to obtain quantitative scores for substrates in cells and fill gaps in the literature. Studying Pgp in the context of MDR, we improve Pgp specificity scores by leveraging new Pgp expression (cell lines, tissues) and function (drug screening) datasets. We experimentally and computationally integrate functional dataset information to better understand Pgp specificity using an approach based on underlying Michaelis-Menten enzyme kinetics. We obtain consensus scores for Pgp specificity across [~]150 FDA approved oncology drugs and validate them experimentally in a subset of 76 substrates selected to represent the spectrum of drugs for Pgp specificity. These scores can be used to calibrate clinical diagnostics (Pgp expression), and our experimental platform can be used to quantify Pgp function in clinical samples. Overall, we develop a parallel computational and experimental procedure to estimate Pgp selectivity in live cells. This procedure can be expanded to other drug transporters which contribute to MDR to further characterize this phenotype quantitatively. Significance StatementMDR is facilitated through the action of drug transporters which are upregulated in cancer. Even though selective inhibitors have been designed to decrease drug efflux, they failed clinically. So, current clinical practice is to select non-substrates. However, non-substrates are difficult to define. Here, we have developed a quantitative platform for characterizing MDR in cancer that factors in gene expression and enzyme kinetics. Our computational and experimental platform successfully identified the spectrum of substrates for Pgp from the FDA approved oncology drug library. This quantitative approach reflects the multigene phenotype of cancer drug resistance and can be applied to other MDR transporter genes to optimize drug selection clinically.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Ray, A. E., Douglass, E. F.. 2024-11-03. A Quantitative Approach for Assessing Multidrug Resistance in Cancer. https://doi.org/10.1101/2024.11.02.621654

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

Biochemical reassessment of the activation of PANK1 by SGLT2 inhibitors

Although SGLT2 inhibitors (SGLT2i) show cardiovascular benefits in addition to glycemic control, their molecular target for cardiovascular effect remains unclear. A recent study reported that two SGLT2i, empagliflozin and dapagliflozin, directly activate pantothenate kinase 1 (PANK1), which mediate their cardioprotective effect. PANK1 phosphorylates pantothenate with ATP to yield 4'-phosphopantothenate and ADP, representing the rate-limiting enzyme of coenzyme A (CoA) biosynthesis. We therefore reassessed this claim using purified recombinant human PANK1. The malachite green assay detected free inorganic phosphate (Pi) but neither ADP nor 4'-phosphopantothenate and its signals do not reflect PANK1 activity. In the ADP-Glo assay, empagliflozin and dapagliflozin did not stimulate PANK1 under either basal conditions or acetyl-CoA feedback inhibition, while the activator PZ-2891 enhanced the activity of PANK1. These results show that SGLT2i do not directly activate PANK1, challenging the proposed PANK1-dependent cardioprotection mechanism.

biochemistry↗

Experimental and computational mapping reveals preferential nanobody targeting of the intracellular cavity of the amino acid transporter BasC

Nanobodies are valuable tools for stabilizing and investigating membrane transporters, but the systematic characterization of large nanobody collections remains experimentally demanding. Here, we combined biochemical and transport assays, experimental structural data and AlphaFold3 modelling to characterize a repertoire of 29 nanobodies targeting the bacterial amino acid transporter BasC. By exploiting the random orientation and asymmetric apparent substrate affinities of BasC in proteoliposomes, comparison of nanobody-mediated influx and efflux inhibition enabled experimental assignment of binding sidedness. The collection showed a marked bias towards inhibition from the intracellular face, whereas only two, Nb58 and Nb78, were identified as extracellular binders. Compatibility assays and a 6.1 [A] crystallographic map of the BasC-Nb53-Nb58 complex supported the simultaneous binding of Nb53 and Nb58 to opposite sides of the transporter and validated the functional sidedness assignment. AlphaFold3 generated high-confidence interaction models for 16 of the 29 complexes. Ten of these models targeted the large intracellular cavity, revealing recurrent epitope clusters. The predicted binding modes of Nb53, Nb71 and Nb74 agreed with available experimental structures, supporting the accuracy of these predictions. Notably, these three nanobodies had previously provided the most informative structural and smFRET data. Our results show that transport-based sidedness measurements together with confidence-filtered structural predictions can define the functional and structural landscape of a nanobody repertoire. This integrated approach may provide a virtual structural screening strategy to prioritize nanobodies, identify dominant epitope regions and select potentially compatible combinations for experimental and structural studies.

biochemistry↗

Intraspecific glucosinolate chemodiversity in Cardamine hirsuta

Within some plant species, a high intraspecific chemical variation, termed chemodiversity, can be found in the composition of specialized metabolites. For Brassicales, glucosinolates are highly characteristic. Their composition is genetically determined but variation has been found within species and between organs in different species. Cardamine hirsuta is increasingly being used as genetic model species, but until now, little was known about its genetically-based variation in glucosinolates. Thus, we aimed to characterize glucosinolate profiles, their putative genetic variation and their chemodiversity in established accessions and wild-collected material. We analyzed the glucosinolate profiles of leaves and roots from offspring, grown under standardized conditions, of 18 accessions collected in nine countries. Glucosinolates were quantified by HPLC-DAD and identities were confirmed by UHPLC-QToF-MS/MS. Glucosinolate composition was analyzed in biosynthetic terms, compared across samples with principal component analysis and chemodiversity was quantified as glucosinolate richness and Shannon diversity. In total, 14 glucosinolates were confirmed across samples. Two main sources of variation among accessions were the relative levels of but-3-enyl- versus pent-4-enylglucosinolate and of benzylglucosinolate versus phenethylglucosinolate. An almost universal presence of 1-methoxyindol-3-ylmethylglucosinolate in roots but not leaves was observed, along with quantitative contrasts between leaves and roots. The glucosinolate composition varied profoundly among accessions and between leaves and roots, while offspring within accessions were mostly consistent in their profiles. Even accessions collected in close proximity produced distinct profiles, with no clear separation along latitude or longitude. Our study highlights two independent and chemically simple traits of apparently genetic nature, namely the extent of chain elongation of methionine-derived and of phenylalanine-derived glucosinolates. Their independent occurrence is a main factor shaping the glucosinolate profiles among accessions. High variation was also observed at a local scale, highlighting complex genetic variation in glucosinolate biosynthesis in the species throughout Europe. Moreover, within individuals different organs showed clearly distinct profiles, indicating organ-specific biosynthesis. The genetic basis and ecological consequences of this variation need to be explored in future studies.

biochemistry↗